Cargando…

Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study

INTRODUCTION: This study investigated glycaemic control in individuals with type 1 (T1D) or type 2 diabetes (T2D) 6 months after initiating fast-acting insulin aspart (faster aspart) in a real-world setting. METHODS: This was a single-arm, observational study using extracted patient data from the IB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lane, Wendy, Faurby, Mads, Husemoen, Lise Lotte N., Markovich, Dmitriy L., Rathor, Naveen, De Block, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586136/ https://www.ncbi.nlm.nih.gov/pubmed/34637112 http://dx.doi.org/10.1007/s13300-021-01165-0

Ejemplares similares

Association of postprandial and fasting plasma glucose with HbA1c across the spectrum of glycaemic impairment in type 2 diabetes
por: Valensi, Paul, et al.
Publicado: (2017)

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9)
por: Lane, Wendy S., et al.
Publicado: (2020)

The association between anti‐insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast‐acting insulin aspart in children and adolescents with type 1 diabetes
por: Biester, Torben, et al.
Publicado: (2020)

Effective Overall Glycaemic Control with Fast-Acting Insulin Aspart Across Patients with Different Baseline Characteristics: A Post Hoc Analysis of the Onset 9 Trial
por: Lane, Wendy, et al.
Publicado: (2022)

Use of fast‐acting insulin aspart in insulin pump therapy in clinical practice
por: Evans, Mark, et al.
Publicado: (2019)

Improvements in Glycemic Control Achieved by Altering the t(max) Setting in the iLet(®) Bionic Pancreas When Using Fast-Acting Insulin Aspart: A Randomized Trial
por: Russell, Steven J., et al.
Publicado: (2021)

Understanding Patients’ Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market
por: Murthy, Sreenivasa, et al.
Publicado: (2021)

Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide
por: Kildegaard, Jonas, et al.
Publicado: (2019)

Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin
por: Evans, Marc, et al.
Publicado: (2019)

Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes
por: Zijlstra, Eric, et al.
Publicado: (2017)

Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions
por: Hövelmann, Ulrike, et al.
Publicado: (2017)

Fast-Acting Insulin Aspart in Patients with Type 1 Diabetes in Real-World Clinical Practice: A Noninterventional, Retrospective Chart and Database Study
por: Lind, Marcus, et al.
Publicado: (2023)

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
por: Haahr, Hanne, et al.
Publicado: (2018)

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes
por: Bowering, K., et al.
Publicado: (2018)

Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18‐week, open‐label, phase 3 trial (onset 3)
por: Rodbard, Helena W., et al.
Publicado: (2017)

A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes
por: Melzer-Cohen, Cheli, et al.
Publicado: (2019)

Exploring the Burden of Mealtime Insulin Dosing in Adults and Children With Type 1 Diabetes
por: Lane, Wendy, et al.
Publicado: (2021)

Healthcare costs and hospitalizations in US patients with type 2 diabetes and cardiovascular disease: A retrospective database study (OFFSET)
por: Evans, Marc, et al.
Publicado: (2022)

Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis
por: Dutta, Deep, et al.
Publicado: (2023)

Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences
por: Haahr, Hanne, et al.
Publicado: (2019)

A randomized, multicentre trial evaluating the efficacy and safety of fast‐acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5)
por: Klonoff, David C., et al.
Publicado: (2019)

Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast‐acting insulin aspart compared with insulin aspart
por: Basu, Ananda, et al.
Publicado: (2018)

Projected long‐term outcomes in patients with type 1 diabetes treated with fast‐acting insulin aspart vs conventional insulin aspart in the UK setting
por: Russell‐Jones, David, et al.
Publicado: (2017)

Fast‐acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose‐lowering effect compared with insulin aspart
por: Pieber, Thomas R., et al.
Publicado: (2019)

Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
por: Havelund, Svend, et al.
Publicado: (2015)

The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective
por: Leelarathna, Lalantha, et al.
Publicado: (2018)

Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study
por: Ozer, Kerem, et al.
Publicado: (2021)

Patterns of new glucagon‐like peptide‐1 receptor agonist use in patients with type 2 diabetes during 2014–2019 from a US database: prescriber and patient characteristics
por: Lingvay, Ildiko, et al.
Publicado: (2023)

Fast‐acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose‐lowering effect relative to insulin aspart
por: Shiramoto, Masanari, et al.
Publicado: (2017)

Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial
por: Buse, John B., et al.
Publicado: (2018)

Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial
por: Mathieu, Chantal, et al.
Publicado: (2018)

Fast start for CERN accelerator
por: Saxby, G
Publicado: (1970)

When to start: not so fast
por: Lundgren, J
Publicado: (2012)

Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
por: Heise, T., et al.
Publicado: (2015)

Association of built environment characteristics with adiposity and glycaemic measures
por: Lee, J. J., et al.
Publicado: (2017)

Use of short-acting insulin aspart in managing older people with diabetes
por: Marouf, Eltayeb, et al.
Publicado: (2009)

A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes
por: Heise, Tim, et al.
Publicado: (2017)

Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials
por: Hansen, Morten, et al.
Publicado: (2012)

Fail fast or win big: the start-up plan for starting now
por: Primento Digital
Publicado: (2016)

Fail fast or win big : the start-up plan for starting now
por: Schroeder, Bernhard
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7ql7setl4uer1lgl05kbfdihr6